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Objective.Wilson’s disease is a disorder of coppermetabolismwhich is fatal without treatment.The great number of disease-causing
ATP7B gene mutations and the variable clinical presentation of WDmay cause a real diagnostic challenge. The emergence of next-
generation sequencing provides a time-saving, cost-effective method for full sequencing of the whole ATP7B gene compared to the
traditional Sanger sequencing.This is the first report on the clinical use of NGS to examineATP7B gene.Materials andMethods. We
used Ion Torrent Personal Genome Machine in four heterozygous patients for the identification of the other mutations and also in
two patients with no knownmutation. One patient with acute on chronic liver failure was a candidate for acute liver transplantation.
The results were validated by Sanger sequencing.Results. In each case, the diagnosis ofWilson’s disease was confirmed by identifying
the mutations in both alleles within 48 hours. One novel mutation (p.Ala1270Ile) was found beyond the eight other known ones.
The rapid detection of the mutations made possible the prompt diagnosis of WD in a patient with acute liver failure. Conclusions.
According to our results we found next-generation sequencing a very useful, reliable, time-saving, and cost-effective method for
diagnosing Wilson’s disease in selected cases.
1. Introduction
Wilson’s disease (WD) is a rare autosomal recessive disorder
of copper metabolism. ATP7B gene mutation is in the back-
ground of the excessive copper accumulation which is fatal
without treatment. More than 550 disease-causing mutations
of the gene located at chromosome 13q14.3-q21.1 consisting of
21 exons have been identified [1].
The geographical distribution of the mutations of the
ATP7B gene is inhomogeneous [2–5]. In Hungary the
p.His1069Gln mutation is the most frequent one with 71%
prevalence among the patients [6].
The variable clinical presentation of WD may cause a
real diagnostic challenge.The suspicion of the disease usually
arises when hepatic or neurologic-psychiatric symptoms
appear. Low ceruloplasmin level and presence of Kayser-
Fleischer ring could support the diagnosis, but in many cases
only genetic testing could confirm it. Genetic investigation of
asymptomatic siblings has an extreme importance, since the
early treatment could prevent themanifestation of the disease
[7]. In acute liver failure urgent genetic testing of all known
mutations may strengthen the diagnosis of Wilson’s disease.
The emergence of next-generation sequencing (NGS)
provides a time-saving, cost-effectivemethod for full sequen-
cing of the whole ATP7B coding sequence compared to the
traditional Sanger sequencing. The NGS technology is based
on the detection of a signal during the synthesis of the
DNA strand, and therefore the synthesis does not need to
be terminated for the perception. On the other hand, several
DNA strands can be examined simultaneously [8].
This is the first report on the clinical use of NGS to
examine ATP7B gene in WD patients including doubtful
cases. We used Ion Torrent Personal Genome Machine in
heterozygous patients for the identification of the other
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mutations and also in patients with no known mutation
including one with acute on chronic liver failure.
2. Materials and Methods
The method we used for the genetic testing has been pre-
viously published by our group for screening of neurofibro-
matosis type 1 gene [9].
2.1. Biological Samples and DNA Isolation. Six (five male
and one female) WD patients, four heterozygous for ATP7B
p.His1069Gln mutation identified by fast PCR test and two
with unknown mutation, were selected for this study. The
patients were diagnosed and treated at the 1st Department
of Internal Medicine, Semmelweis University, Budapest. The
diagnosis was based on the international WD score system
published in 2003 [10], and each patient had 4 or more
scores. The study was approved by the Semmelweis Univer-
sity’s Committee of Research Ethics and was conducted in
accordance with the Helsinki Declaration. All patients gave
written informed consent.
Genomic DNA was isolated from 200𝜇L of periph-
eral blood using ReliaPrep Blood gDNA Miniprep System
(Promega, Madison, WI). Briefly, the blood samples were
digested with Proteinase K solution in the presence of Cell
Lysis Buffer, and, after 10min of incubation at 56∘C, DNA
was bound to ReliaPrep Binding Column. After three washes,
DNA was eluted into 50𝜇L of nuclease-free water. The
concentration of the isolated DNA was determined with
Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad,
CA).
2.2. Ion Torrent Sequencing. ATP7B (21 coding exons) ampli-
cons were designed using the AmpliSeq Designer software
(Life Technologies, CA, USA), targeting the complete coding
sequence of ATP7B gene, resulting in a total of 55 amplicons.
To gain a higher coverage of the coding exons, we designed
the primers to also flank some parts of the introns. Amplicon
library was prepared using the Ion AmpliSeq Library Kit
2.0 (Life Technologies, CA, USA); briefly, multiplex primer
pools were added to 10 ng of genomic DNA and amplified
with the following PCR cycles: at 99∘C for 2min, at 99∘C
for 15 s, and at 60∘C for 4min (18 cycles), and holding
on at 10∘C. Primers were partially digested using a FuPa
reagent, and then sequencing adapters were ligated to the
amplicons. The library was purified in multiple times using
the Agencourt AMPure XP Reagent (Beckmann Coulter,
CA, USA). The concentration of the final library was deter-
mined by fluorescent measurement on Qubit 2.0 instrument
(Life Technologies, CA, USA). Template preparation was
performed with Ion OneTouch kit (Life Technologies, CA,
USA) on semiautomatic Ion OneTouch instrument using
an emPCR method. After breaking the emulsion, the non-
templated beads were removed from the solution during
the semiautomatic enrichment process on Ion OneTouch ES
(Life Technologies, CA, USA) instrument. After adding the
sequencing primer and polymerase, the fully prepared Ion
Sphere Particle (ISP) beads were loaded into an Ion 314 v2
sequencing chip, and the sequencing runs were performed
using the Ion PGM 200 Sequencing kit v2 (Life Technologies,
CA, USA) with 500 flows.
2.3. Sanger Sequencing Validation. The PCR primers were
designed using Primer3Plus (http://primer3plus.com/) soft-
ware. Roche FastStart TaqMan Probe Master (Roche) kit was
used to amplify the target regions and the PCR program
was as follows: 95∘C for 10min, 40 cycles of 95∘C for 30 s,
60∘C for 30 s, and 72∘C for 45 s, and the final step was
72∘C for 5min. PCR products were enzymatically cleaned
using ExoSAP IT (Affymetrix, Santa Clara, CA) according
to the manufacturer’s instructions. Sanger sequencing was
performed using BigDye Terminator v3.1 Cycle Sequencing
Kit (Life Technologies) using an ABI 3130 instrument (Life
Technologies).
2.4. Data Analysis. Data from the Ion Torrent runs were
analyzed using the platform-specific pipeline software Tor-
rent Suite v3.6 for base calling, trim adapter and primer
sequences, filter out poor quality reads, and demultiplex the
reads according to the barcode sequences. Briefly, TMAP
(https://github.com/iontorrent/TMAP) algorithm was used
to align the reads to the hg19 human reference genome, and
then the variant caller plug-in was selected to run to search
for germ line variants in the targeted regions. The variant
caller algorithm parameters were more relaxed to avoid false
negative cases. Integrative Genomics Viewer was used for
visualization of the mapped reads. Variants were reviewed
and annotated using dsSNP (http://www.ncbi.nlm.nih.gov
/projects/SNP/) and Wilson Disease Mutation Database
(http://www.wilsondisease.med.ualberta.ca/index.asp). For
variant interpretation, Ingenuity Variant Analysis Pipeline
(Ingenuity, Rewood City, CA) was also used. Pathogenic
status of the variant was stated if it was a missense variant
with <1%minor allele frequency and/or the variant was listed
in the literature or in the databases as a pathogenic alteration.
All of the deleterious variants were confirmed by Sanger
sequencing. The Sanger sequence data were investigated
using ABI Sequence Scanner 1.0 (Life Technologies) and
BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html)
software.
3. Results
The demographic and clinical characteristics of the patients
are shown in Table 1. One patient without known mutation
was critically ill with acute on chronic liver disease. The
typical laboratory findings (ALT 90, AST 178, ALP 88, and
bilirubin 247) proposed Wilson’s disease. The diagnosis was
strengthened by genetic testing making possible the liver
transplantation via Eurotransplant program in Patient 5 with
acute on chronic liver failure.
In each case, the diagnosis of Wilson’s disease was
confirmed by identifying the mutations in both alleles. The
results were available within 48 hours.
The average read number per sample was 134386, with
an average 1X on-target coverage of 99.46%. The mean raw
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Table 1: Demographic and clinical characteristics of the patients.
Gender Age at onset(year) KFR Neu HA Urin Cu Biopsy Cerul (g/L) ATP7B status WD score
a Phenotype
Patient 1 Female 12 P A A ++ ND 0.18 p.Met769-fs/p.His1069Gln 6 S
Patient 2 Male 17 A P A + ND 0.05 p.Ala1063Val/p.His1069Gln 6 N1
Patient 3 Male 8 P A A ++ +b 0.06 p.His1069Gln/p.Gln1351Stop 8 H2
Patient 4 Male 17 P A A + ND 0.03 p.Ala1135-fs/p.Leu1305Pro 5 H2
Patient 5 Male 44 A A A ++ ND 0.08 p.Ala1270Ile/c.1707+2dupT 4 H1
Patient 6 Male 14 P P A ND ND 0.04 p.Arg969Gln/p.His1069Gln 7 N2
KFR: Kayser-Fleischer ring; Neu: neurological signs and/or CT/MRI alterations; HA: hemolytic anemia; Urin Cu: urinary copper, 1-2X ULN: +, >2x ULN or
positive D-penicillamine challenge: ++; Cerul: ceruloplasmin, P: present; A: absent; ND: not done; S: sibling; H1: acute liver failure; H2: chronic liver disease;
N1: neurological symptoms with liver disease; N2: only neurological symptoms.
aAccording to the international score system, 4 or more scores, diagnosis of WD is highly likely. bRhodanine positivity.
T
(a1) (a2)
(b1) (b2)
CGGGGAGTCAWTGACCCCATCC GCACCCACAGTACTTACTGGCCG TGAGCTGACAGTWARKAAYGG
2502401009010090340 350
GGGATGGGGTCAWTGACTCCCCG
Figure 1: The identified mutations of patient 5. Both c.3809A>T (causing amino acid change p.Ala1270Ile) and c.1707+2dupT mutations
are confirmed by Sanger-sequencing. The 3809A>C and A>G mutations are known, but the A>T substitution is a novel alteration at this
position. (a1) Visualizing the alignment of the sequencing reads covering the ATP7B c.3809A>T heterozygous point mutation. The coverage
was 400-fold (211-fold reference and 189-fold variant coverage). (b1) Validating our finding with Sanger sequencing, red arrow indicates the
position of the point mutation. The mutation is present in both directions. (a2) Visualizing the alignment of the sequencing reads covering
theATP7B c.1707+2dupT heterozygous insertionmutation.The coverage was 399-fold (188-fold reference and 211-fold variant coverage). (b2)
Validating our finding with Sanger-sequencing, red arrow indicates the position of the insertion. The mutation is present in both directions.
accuracy was 99.2%. The average base coverage depth was
1883 (Table 2). The number of identified variants per sample
was between 8 and 13; however most of them were known as
non-disease-causing variants.
Overall, we found nine disease-causing variants. The
most frequent mutation was p.His1069Gln (exon 14, ATP
loop) detected in four patients. One novel missense muta-
tion (p.Ala1270Ile, exon 18, ATP hinge vide Figure 1) and
threewell-knownmissensemutations (p.Arg969Gln, exon 13,
TM6; p.Ala1063Val, exon 14, ATP loop, and p.Leu1305Pro,
exon 19 bet ATP hinge/TM7), three frame-shift mutations
(c1707+2dupT, exon 4, Cu6; p.Met769-fs exon 8 TM4, and
p.Ala1135-fs exon 15 ATP loop), and one nonsense mutation
(p.Gln1351Stop, exon 20, TM8) were detected. All of these
variants had been validated by Sanger sequencing.
4. Discussion
Although there is an international diagnostic score system for
WD [10], the set-up of the diagnosis remains a great challenge
in many cases. The signs and symptoms are very colorful,
and most of the criteria have relatively low sensitivity and/or
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Table 2: Per sample and per amplicon coverage data.
Chromosome Ampliconstart
Amplicon
end Amplicon ID Gene ID Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
chr13 52520358 52520440 AMPL1102520485 ATP7B 812 484 378 9467 3557 3275
chr13 52542530 52542653 AMPL1102672008 ATP7B 951 390 145 3149 5510 3183
chr13 52538909 52539030 AMPL1404436522 ATP7B 9 2 2 2 4 46
chr13 52523735 52523838 AMPL561308261 ATP7B 417 285 89 245 683 2611
chr13 52518244 52518356 AMPL561308388 ATP7B 1140 520 339 7934 6166 3595
chr13 52516492 52516613 AMPL561312436 ATP7B 600 309 70 1510 3218 2152
chr13 52515134 52515253 AMPL561312709 ATP7B 799 287 74 1340 3258 2733
chr13 52520435 52520563 AMPL561312859 ATP7B 622 308 149 409 906 2130
chr13 52511616 52511742 AMPL561313522 ATP7B 343 233 58 1462 2168 1069
chr13 52548475 52548562 AMPL561315457 ATP7B 740 557 248 660 1251 3869
chr13 52548014 52548135 AMPL561316164 ATP7B 506 109 93 244 614 3077
chr13 52535952 52536073 AMPL561319098 ATP7B 345 332 62 1845 3919 1350
chr13 52532445 52532575 AMPL561319439 ATP7B 495 382 75 260 477 2421
chr13 52518332 52518433 AMPL561320185 ATP7B 445 574 270 852 1305 2147
chr13 52511401 52511536 AMPL561321003 ATP7B 899 422 181 3036 4216 2756
chr13 52523839 52523934 AMPL561322321 ATP7B 802 389 181 3872 3781 2867
chr13 52520556 52520638 AMPL561322791 ATP7B 836 630 362 9187 4465 3540
chr13 52534277 52534394 AMPL561324803 ATP7B 670 295 126 3402 3937 2458
chr13 52542654 52542747 AMPL561326888 ATP7B 755 503 272 811 1791 3775
chr13 52524407 52524535 AMPL561327019 ATP7B 215 139 38 126 250 1023
chr13 52516614 52516708 AMPL561328057 ATP7B 546 401 206 591 1259 2779
chr13 52515254 52515365 AMPL561328062 ATP7B 768 466 191 508 1239 3144
chr13 52513223 52513345 AMPL561328524 ATP7B 454 382 113 239 732 1771
chr13 52548563 52548672 AMPL561329883 ATP7B 836 384 149 3334 4618 3056
chr13 52511743 52511824 AMPL561330934 ATP7B 718 556 323 946 1461 3040
chr13 52532576 52532683 AMPL561335846 ATP7B 671 433 227 5882 4370 2749
chr13 52511497 52511615 AMPL561335849 ATP7B 813 494 353 857 1761 3297
chr13 52549016 52549114 AMPL561337443 ATP7B 453 347 167 3818 3121 2050
chr13 52534395 52534476 AMPL561338245 ATP7B 734 542 476 1282 2378 2732
chr13 52539048 52539119 AMPL561339230 ATP7B 532 448 394 9393 3563 2527
chr13 52544567 52544690 AMPL561342268 ATP7B 806 449 130 2523 3519 2674
chr13 52548673 52548782 AMPL561343055 ATP7B 512 446 158 513 1052 3022
chr13 52548136 52548260 AMPL561345064 ATP7B 826 442 128 2692 4578 2624
chr13 52549115 52549227 AMPL561347059 ATP7B 469 369 144 398 771 2612
chr13 52539120 52539203 AMPL561347740 ATP7B 787 737 877 3031 2553 4243
chr13 52509711 52509847 AMPL561353128 ATP7B 329 280 70 208 669 2063
chr13 52549228 52549346 AMPL561354995 ATP7B 720 232 59 900 2717 2418
chr13 52508853 52508964 AMPL561358361 ATP7B 660 455 181 4930 3832 2325
chr13 52548783 52548894 AMPL561361353 ATP7B 1286 639 267 7815 7277 3588
chr13 52544691 52544813 AMPL561365512 ATP7B 542 354 150 336 898 2919
chr13 52508959 52509084 AMPL561366430 ATP7B 694 574 217 630 1344 2208
chr13 52524093 52524178 AMPL561367088 ATP7B 368 315 5 31 82 2778
chr13 52524179 52524298 AMPL561373391 ATP7B 725 390 108 2697 4100 2724
chr13 52544814 52544931 AMPL561373418 ATP7B 235 52 34 618 1093 1651
chr13 52548893 52549018 AMPL561375011 ATP7B 498 471 103 239 550 2166
chr13 52509084 52509181 AMPL561375394 ATP7B 719 461 144 5037 3879 2163
chr13 52531644 52531756 AMPL561379526 ATP7B 512 234 80 1601 2656 2155
chr13 52548255 52548381 AMPL561399016 ATP7B 467 446 98 286 676 2965
chr13 52548382 52548474 AMPL561401395 ATP7B 247 124 69 1000 357 2414
chr13 52513106 52513229 AMPL561308165 c.3699+27T>C,ATP7B 560 372 88 1778 3799 2176
chr13 52585387 52585514 AMPL561308108 c.-36C>T, c.-75A>C,ATP7B 294 287 110 313 616 2859
chr13 52585831 52585931 AMPL1275480480 ATP7B 493 397 129 807 780 1389
chr13 52585851 52585971 AMPL1275480698 ATP7B 458 140 55 1205 1642 811
chr13 52534093 52534223 AMPL1275484758 ATP7B 140 230 35 69 187 2149
chr13 52585478 52585613 AMPL561317674 ATP7B 560 186 58 997 1619 1979
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specificity. Although genetic testing in itself can ascertain the
diagnosis, it is limited by the great variety of the mutations.
It is also difficult to screen the siblings of a WD patient,
especially of those who do not have identified mutations,
since the abnormal laboratory results of copper metabolism
may occur in heterozygous carriers. The tight observation of
these siblings and the doubt if they are affected can make
their life very stressful and uncomfortable. The detection of
the mutations in the index patient and searching for the same
in the siblings can resolve this problem.
The whole gene analysis of ATP7B by PCR and capillary
sequencing in a large cohort of WD patients has been
recently published [11]. According to our knowledge based
on PubMed data this is the first report on next-generation
sequencing of the ATP7B gene for genetic diagnosis of
Wilson’s disease in a clinical setting. Since the disease-causing
mutations may occur in the whole length of the gene and
every exon could be affected, the genetic examination by
classical methods is ponderous and time-consuming.
Our study clearly shows the great benefit of NGS. The
compound heterozygosity has been proved in each patient
within a very short examination time. Previously, we pub-
lished that p.His1069Gln mutation is most common one
in Hungary (71%) similar to other Central and Eastern
European countries [6, 12–14]. Results of this study are in
concordance with the former epidemiological data, since this
mutation was confirmed in the majority of the cases, in 4
out of 6. Among the eight other mutations we found, there is
one novel mutation in exon 18 which is a missense mutation
causing an asparagine-isoleucine change in the transporter.
Interestingly, the mutations beyond p.His1069Gln occurred
only in one allele of a single patient.
However, it is already well known that p.His1069Gln
homozygous mutation tends to relate with neurological
symptoms; the effect of other infrequent mutations on the
phenotype is hard to be examined due to the low number of
cases (vide Table 1) [15].
p.Ala1063Val mutation detected in one patient who has
been diagnosed with WD prior to genetic testing is thought
to be a non-disease-causing variant according to the Wilson
Disease Mutation Database, although only one publication
suggested that it might be a polymorphism [4]. On the other
hand, subsequent data show that it might be a variant of
unknown significance (VUS) [16]. Furthermore it was the
one and only nucleotide change in a WD family analyzed
by Loudianos et al. [17]. Overall it seems that p.Ala1063Val
mutation still might be associated with Wilson’s disease.
NGS gave a tremendous benefit for a 47-year-old patient
with acute on chronic liver failure. Although nearly all
patients with ALF due to Wilson’s disease are potentially
diagnosed (or suspicion is very high) with use of simple
biochemical and laboratory criteria (ratio of alkaline phos-
phatase to bilirubin, ratio of AST to ALT, and Coombs
negative hemolytic anemia) [18], the diagnosis may require
an urgent genetic testing of all mutations. In some patients
the laboratory data alone cannot give enough scores in
the international score system [10], which is required by
Eurotransplant program for donor liver allocation. In our
case, the results of D-penicillamine test and the NGS arrived
simultaneously, confirming Wilson’s disease. According to
the actual regulation of Eurotransplant Organization in case
of acute on chronic liver failure only WD and Budd-Chiari
syndrome are accepted as indication for urgent transplan-
tation. Identifying mutations in both alleles gave a clear-cut
evidence of the disease despite lack of Kayser-Fleischer ring,
lack of neurological symptoms, and p.His1069Gln mutation.
Thanks to the quick diagnosis the patient has been trans-
planted within two days and survived, and he is still in good
condition one year later.
5. Conclusion
According to our results we found next-generation sequenc-
ing to be a very useful, reliable, time-saving, and cost effective
method for diagnosing Wilson’s disease in selected cases.
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